PT  - JOURNAL ARTICLE
AU  - Yaghoubi, Mohsen
AU  - Mansell, Kerry
AU  - Vatanparast, Hassanali
AU  - Zeng, Wu
AU  - Javanbakht, Mehdi
AU  - Farag, Marwa
TI  - Patient-level micro-simulation model for evaluating the future potential cost–effectiveness of pharmacy-based interventions in the control and management of diabetes-related complications in Canada
AID  - 10.1101/2020.03.10.20033597
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.10.20033597
4099  - http://medrxiv.org/content/early/2020/03/13/2020.03.10.20033597.short
4100  - http://medrxiv.org/content/early/2020/03/13/2020.03.10.20033597.full
AB  - Background The increased risk of complications among diabetes patients poses a serious threat to population health. Pharmacy-based interventions can decrease the burden of diabetes and its related complications. This study evaluates the cost-effectiveness of pharmacy-based interventions and offers insights on the practicality of their adoption by health practitioners.Methods We developed population-based micro-simulation model using 2,931 patients with diabetes in Canada. We used the risk equations on the UK Prospective Diabetes Study (UKPDS) to estimate the incidence and mortality of four of the most common diabetes-related complications (heart failure, stroke, amputation, and blindness). We extrapolated the potential effects of pharmacy interventions on reducing time-varying risk factors for diabetes complications. Cost was quantified as the annual cost of complications; and, the cost associated with pharmacy-based interventions. The final outcomes were the incremental costs per quality-adjusted life years (QALY) gained. Both deterministic and probabilistic sensitivity analysis were conducted to examine the robustness of the ratio.Result Pharmacy-based interventions could prevent 155 preventable deaths, 159 strokes, 29 cases of blindness, 24 amputations, and 19 heart failures across the lifetime of 2,931 patients. In addition, an estimated 953 QALYs (0.32 per patient) would be gained among the intervention group. Per QALY, the incremental discounted cost is $3,928, suggesting that pharmacy-based interventions are likely cost-effective compared to usual care. At an ICER threshold of $50,000, over 92% of the simulation remains cost-effective.Conclusion Pharmacist-based interventions targeted at addressing the development of diabetes-related complications among Canadian patients have the potential to offer a cost-effective strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are available upon request